Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Shares Outstanding (Weighted Average) (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Shares Outstanding (Weighted Average) for 13 consecutive years, with $166.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) rose 9.35% year-over-year to $166.7 million, compared with a TTM value of $166.7 million through Dec 2025, up 9.35%, and an annual FY2025 reading of $166.7 million, up 9.35% over the prior year.
  • Shares Outstanding (Weighted Average) was $166.7 million for Q4 2025 at Heron Therapeutics, up from $159.5 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $166.7 million in Q4 2025 and bottomed at $98471.0 in Q4 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $120.1 million, with a median of $119.4 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Weighted Average) tumbled 99.89% in 2021, then skyrocketed 110466.56% in 2022.
  • Year by year, Shares Outstanding (Weighted Average) stood at $98471.0 in 2021, then surged by 110466.56% to $108.9 million in 2022, then rose by 26.87% to $138.1 million in 2023, then rose by 10.36% to $152.4 million in 2024, then rose by 9.35% to $166.7 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for HRTX at $166.7 million in Q4 2025, $159.5 million in Q3 2025, and $152.4 million in Q4 2024.